diagnostics when it does not involve a disease causing variant. Although this might be true to some extent, it is a rather unsatisfactory explanation in this era of deep DNA sequenc ing. Nevertheless, Luo and colleagues' findings should provoke a re assessment of the extensive global mtDNA sequencing data available, for those wishing to unearth further instances of atypical heteroplasmy. If the paternal con tribution to mtDNA is more common than previously realized, this could alter some esti mated timings of human evolution, because these are often based on predictions of mtDNA sequence variation under the assumption of exclusive maternal inheritance.
Although biparental inheritance of mtDNA and heteroplasmy coincided with disease symptoms in some of the individuals studied by Luo et al., the authors' data do not demon strate a causal link with disease. In fact, we cannot be certain that the study participants have mitochondrial disease, because no spe cific examinations to confirm this diagnosis are reported. Further study is needed to iden tify more cases of potential paternal mtDNA inheritance, and to determine the functional consequences of such heteroplasmy. Notably, this knowledge is relevant to mitochondrial donation therapy ("threeparent babies"), which aims to prevent the transmission of dis easecausing mtDNA to offspring 14 , but which can also potentially generate individuals with two types of mtDNA, one from the donor and another from the mother.
Could the amount of paternal mtDNA in a fertilized egg or developing embryo be delib erately boosted to diminish the adverse effects of mutant maternal mtDNA when this is pre sent? This is an interesting option, but still far from reality. In addition to evading elimina tion, paternal mtDNA molecules would need to have a considerable replicative advantage over maternal ones to reach meaningful proportions.
Will Luo and colleagues' findings affect the counselling of individuals carrying disease causing mtDNA mutations who are consid ering having children? Not greatly, because paternal mitochondrial transmission seems to be exceedingly rare in humans. At present, this discovery represents an interesting conceptual breakthrough, rather than one that will directly influence clinical practice.
Previous work 15 has shown that mitophagy, the process by which cells 'eat' their own mito chondria, has a role in the selective elimina tion of paternal mitochondria. Given our rapidly expanding knowledge of mammalian mitophagy in vivo 16 , these rare instances of paternal mtDNA transmission might be attrib uted to defective mitochondrial turnover. The inheritance pattern of paternal mtDNA in Luo and colleagues' study suggests that a yet unidentified gene on one of the autosomes (nonsex chromosomes) is involved in elimi nating paternal mitochondria. The families in whom paternal mtDNA inheritance was observed provide an exciting opportunity to decipher the signalling pathways that modu late paternal mitochondrial elimination and prevent biparental mitochondrial transfer. ■ Thomas G. McWilliams 
P E K K A L A P PA L A I N E N
A ctin is one of the most abundant proteins in our cells. It assembles into filaments that produce force for many processes that are essential to the life of animals, plants and fungi -including cell migration and division, and muscle con traction 1 . The organization and dynamics of actin filaments in cells are regulated by a large array of actinbinding proteins. More over, posttranslational modifications of actinthe addition of certain chemical groups to its aminoacid residues, or their removal -is thought to have a role in controlling the cellu lar functions of actin filaments. However, the proteins that catalyse these changes have been elusive. On page 372, Wilkinson et al. 2 report the identification of the longsought enzyme that catalyses the methylation (addition of a methyl group) of actin, and shed light on the biological role of this posttranslational modification in animals.
Some posttranslational modifications of actin are present in all isoforms (structural variants) of the protein, whereas others are more specific. The protein's aminoterminal region can be modified by acetylation (addi tion of an acetyl group) and arginylation (addition of an arginine aminoacid resi due) 3 . Recent studies identified the enzyme responsible for aminoterminal acetylation of actin and demonstrated that this modification affects the elongation and depolymerization of actin filaments 4, 5 . Most actin isoforms are also methylated at a particular histidine aminoacid residue known as His73, which is close to the site to which one of two nucleotides, ATP or ADP, binds. Hydrolysis of ATP to ADP plus one free phos phate molecule is essential for the turnover of actin filaments, and hence for their ability to produce force in cells. Although methylation of His73 was identified more than five decades ago 6 , the enzyme responsible and the biological functions of this modification have remained unknown.
The study by Wilkinson et al. and a related study published in eLife 7 report that the SETD3 protein is the enzyme that methylates actin at His73 (Fig. 1) . This is the first time an actin methyl transferase (an enzyme that catalyses methylation) has been identified, and also the first time a histidine methyltransferase has been identified in animals. Earlier work suggested that SETD3 methylates lysine aminoacid residues in histone H3 (ref. 8 
How to fine-tune the cell's force producers
Identification of the enzyme that catalyses a site-specific modification of the protein actin reveals how this change modulates the function of the cell's force-producing machinery. See Letter p.372 in mammals, SETD3 is the only enzyme that catalyses the His73 methylation of actin, and that actin is the only substrate of SETD3. They also show that SETD3 and His73 methylation of actin are present in a wide range of organ isms, including plants and animals, but that SETD3 is not present in budding yeast, which also lacks His73methylated actin.
Why does SETD3 methylate actin, but not other proteins? To answer this question, Wilkinson et al. determined the atomic struc ture of SETD3 in complex with a short chain of amino acids (a peptide) that has the same aminoacid sequence as the region of actin around His73. They found that this peptide occupies an extended groove in the domain of SETD3 that is responsible for the enzyme's methyltransferase activity. The interface between SETD3 and the actin peptide has many specific interactions, which explain why SETD3 binds to and methylates only actin.
To examine the biological functions of this posttranslational modification, Wilkinson et al. generated 'knockout' mice and cell lines in which the gene encoding SETD3 was in active. They observed that actin is no longer methyl ated in these models. Surprisingly, the mice lacking SETD3 seemed to be healthy, which demonstrates that methylation of actin at His73 is not essential in mammals. However, female mice lacking SETD3 took longer to give birth than did mice in which this protein was present. The delay resulted from defective contraction of certain muscles of the uterus during labour. Moreover, the migration of SETD3knockout cells in culture was slower than that of wildtype cells. Finally, nonmethylated actin purified from the SETD3knockout cells polymerized slightly more slowly than did methylated actin, and had a faster rate of exchange of nucleo tides on single actin molecules than did actin purified from wildtype cells.
These experiments provide evidence that, despite being evolutionarily conserved across a broad group of organisms, methylation at His73 is not essential for the normal functioning of actin. Instead, this modification seems to finetune the protein's biochemical properties and cellular roles.
Future studies should investigate the SETD3knockout mice in more detail for possible additional differences from wild type mice, and should examine the effects of SETD3 deletion in other model organisms. Also, the effects of His73 methylation on actin biochemistry should be studied more precisely. Previously, analysing these effects was possible only by mutating the His73 residue in actin or by producing human actin in yeast, in which this protein cannot be methylated 9, 10 . The new findings will enable careful sidebyside com parison of wildtype actin and actin that lacks methylation only at His73.
Because His73 is close to the nucleotide binding site of actin, it will be especially interesting to study how this modification affects the functions of proteins that catalyse nucleotide exchange on actin 11 and that rely on ATP hydrolysis and subsequent release of free phosphate for their interactions with actin filaments 12 . ■ 
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